Innovent Laekna begin patient dosing in phase 1/2 trial of three drug combination to treat solid tumours who were resistant to prior anti-PD-1/PD-L1 therapy

Innovent Biologics, Inc., a world-class biopharmaceutical company, and Laekna Therapeutics, a clinical-stage biotechnology company, jointly announced that the first patient has been dosed in a phase 1/2 clinical trial of a three-drug combination therapy (afuresertib + sintilimab + chemotherapy) in patients with specific solid tumours who were resistant to anti-PD-1/PD-L1 therapy at the West China Second Hospital of Sichuan University. This marks a key milestone on the first anniversary of the clinical research partnership established between Innovent and Laekna in July 2021. The study is a multi-center, single-arm, open-label, dose-escalation phase 1/2 clinical study, assessing recommended phase 2 dose (RP2D), safety, tolerability and anti-tumour activity of afuresertib in combination with sintilimab and chemotherapy (nab-paclitaxel or docetaxel) in patients with solid tumors who were resistant to prior anti-PD-1/PD-L1 therapy. The principal investigator of the study is Professor Lin Shen, director of the Department of Gastrointestinal Oncology of Beijing Cancer Hospital. The primary endpoints of the phase 1 dose escalation study are maximum tolerated dose (MTD) and RP2D, and the primary endpoint of the Phase 2 study is overall response rate (ORR). The study is planned to be extended as a multi-regional clinical trial at the pivotal stage. The clinical trial assesses five types of solid tumours, including non-small cell lung cancer (NSCLC), gastric cancer/gastroesophageal junction cancer (GC/GEJC), esophageal cancer (EsC), cervical cancer (CC) and endometrial cancer (EC). The study focuses on the AKT inhibitor, a potential new therapy for drug resistant-cancer, to address the unmet medical needs in cancer immunotherapy resistance and bring hope to solid tumour patients who have received prior anti-PD-1/PD-L1 treatments. The combination therapy consists of Laekna

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!